Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymphoseek vs Blue Dye for Lymph Node Mapping in Melanoma and Breast Cancer
NCT00671918Phase 3Completed
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Apr 2008
- Primary completion
- Jun 2009
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of technetium tc 99m tilmanocept in melanoma and breast cancer, sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Concordance of Blue Dye and Lymphoseek. Started Apr 2008; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
melanomabreast cancer
Beyond the preview
Go deeper on NCT00671918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671918.